COMMUNIQUÉS West-GlobeNewswire

Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices
24/06/2019
NEW YORK and MELBOURNE, Australia, June 24, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced today that the United States Food [...]
R1 Showcases Latest Advancements in Automated Revenue Cycle Management at HFMA 2019 Annual Conference
24/06/2019
Builds largest digital workforce in healthcare revenue cycle with more than four million automated transactions annually to deliver superior financial results CHICAGO, June 24, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc . ( [...]
Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019
24/06/2019
Heidelberg, Germany, June 24, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the presentation of [...]
ALK submits registration application for tree SLIT-tablet in Canada
24/06/2019
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) today announced that the Canadian regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the [...]
RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS
24/06/2019
RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS Milan, 24 June 2019 – Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, today reported that its strategy aimed [...]
Motif Bio Presents New Iclaprim Data at ASM Microbe 2019
24/06/2019
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new iclaprim data were presented [...]
BBS completes final manufacturing steps for CE marking
24/06/2019
BBS – Bioactive Bone Substitutes, an innovator in orthobiologics, today announced that the company’s ARTEBONE ® production line is ready for the audit required for CE marking. Following a successful audit, the certified [...]
ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility
24/06/2019
Inauguration event held last week to officially open 30,000 sq. ft GMP manufacturing facility constructed in Princeton, NJ to produce lead product candidate eryaspase in the United States PRINCETON, N.J. and CAMBRIDGE, [...]
ERYTECH annonce l’ouverture de son nouveau site de production conforme aux BPF à Princeton, dans le New Jersey (États-Unis)
24/06/2019
Inauguration officielle la semaine dernière du site de production conforme aux BPF (Bonnes Pratiques de Fabrication) d’environ 3 000 m 2 construit à Princeton, dans le New Jersey pour produire le candidat médicament, [...]
UK's MHRA renews EAMS Scientific Opinion for Santhera's Idebenone in Duchenne Muscular Dystrophy
24/06/2019
Pratteln, Switzerland, June 24, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has renewed for a further year the Early Access to Medicines [...]
OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
24/06/2019
Event hosted by France Biotech on 24th & 25th June in Paris NANTES, France, June 24, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) will participate in the first HealthTech Investor [...]
Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex’s Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period
24/06/2019
Statistically significant reductions in GGT and ALP in 400mg BID dose over 24-week treatment period (p<0.002 and p<0.001, respectively) GKT831 400mg BID significantly improved multiple quality of life metrics [...]
Les résultats finaux de l’étude de Phase 2 dans la CBP montrent que le candidat médicament anti-fibrotique GKT831 apporte une amélioration statistiquement significative de la GGT et de la PAL tout au long de la période de traitement
24/06/2019
Réduction statistiquement significative de la gamma glutamyl transpeptidase (GGT) et de la phosphatase alcaline (PAL) à la dose de 400 mg deux fois par jour (400 mg BID) au cours de la période de traitement de 24 [...]
Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
23/06/2019
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin- 2 receptor [...]
Kalytera Announces Grant of Stock Options to Directors
21/06/2019
SAN FRANCISCO and TEL AVIV, Israel, June 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has granted stock options [...]
AMAG Pharmaceuticals Announces FDA Approval of Vyleesi™ (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
21/06/2019
The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Distress or Interpersonal Difficulty Due to Low Sexual Desire 1 in 10 Premenopausal Women in the U.S. (Approximately 6 Million Women) [...]
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
21/06/2019
SAN DIEGO, June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of [...]
PSIQ Responds to SEC Trading Suspension
21/06/2019
SUNRISE, Fla., June 21, 2019 (GLOBE NEWSWIRE) -- Profile Solutions, Inc. (OTC Grey: PSIQ) announces its response to the Securities and Exchange Commission ("Commission") temporary Trading Suspension, which commenced at [...]
Avinger to Effect One-for-Ten Reverse Stock Split
21/06/2019
REDWOOD CITY, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of [...]

Pages